D RUG UTILIZATION STUDIER : B RUG AF GLP-1- ANALOGER I D ANMARK Anton Potteg¥rd Klinisk Farmakologi, SDU apottegaard@

  • View
    212

  • Download
    0

Embed Size (px)

Text of D RUG UTILIZATION STUDIER : B RUG AF GLP-1- ANALOGER I D ANMARK Anton Potteg¥rd Klinisk...

  • Slide 1

D RUG UTILIZATION STUDIER : B RUG AF GLP-1- ANALOGER I D ANMARK Anton Pottegrd Klinisk Farmakologi, SDU apottegaard@health.sdu.dk Slide 2 2 Slide 3 The Nordic prescription databases as a resource for pharmacoepidemiological researcha literature review Wettermark et al. Pharmacoepidemiology and Drug Safety (2013) 3 Slide 4 M ETODER Incidensrater Prvalensproportioner Fordeling p enkeltstoffer Persistens (drug survival) Brug af anden medicin Fordeling af daglig dosis () Fordeling af udsteder-typer Regionsforskelle Skvhed i forbrug 4 Slide 5 N ORDISKE MULIGHEDER ? 5 Slide 6 6 Slide 7 7 Slide 8 A NALYSIS What is the incidence rate of treatment with GLP-1 analogues? What is the prevalence proportion of treatment with GLP-1 analogues? Which drugs relevant to the treatment of type 2 diabetes are used by users of GLP-1 analogues? Which dose of GLP-1 analogue do patients use per day? What are the baseline characteristics of incident users? 8 Slide 9 9 Slide 10 10 Slide 11 11 Slide 12 12 Slide 13 Instead, the drug use pattern seen for liraglutide is suspected to be affected by the fact that the drug originates from a Danish drug manufacturer. This assumption is supported by the distribution of consumption (measured in DDD per 1,000 inhabitants per day) of liraglutide in 2012 in the Nordic countries: 2.8 (Denmark), 1.0 (Finland), 1.2 (Iceland), 0.7 (Sweden) and 0.8 (Norway) [3337]. 13 Slide 14 33. The Danish National Institute for Health Data and Disease Control (Statens Serum Insititut). Medstat.dk; Accessed 6 June 2013. Available from: www.medstat.dk/enwww.medstat.dk/en 34. The Norwegian Institute of Public Health. legemiddelforbrug.no. Accessed 6 June 2013. Available from: www.legemiddelforbruk.no www.legemiddelforbruk.no 35. The Swedish National Board of Health andWelfare (Socialstyrelsen). Statistikdatabas fr lkemedel. Accessed 6 June 2013. Available from: http://www.socialstyrelsen.se/statistik/statistikdatabas/lakem edel http://www.socialstyrelsen.se/statistik/statistikdatabas/lakem edel 36. Finnish Medicines Agency (fimea). Lketurvallisuus jalkeinformaatio: Kulutustiedot. Accessed 6 June 2013. Available from: www.fimea.fi/laaketieto/kulutustiedotwww.fimea.fi/laaketieto/kulutustiedot 37. Icelandic Medicines Agency (IMA). Drug consumption in Iceland 20082012. Accessed 6 June 2013. Available from: www.imca.is/imca/statistics/nr/235 www.imca.is/imca/statistics/nr/235 14 Slide 15 15 Slide 16 16 Slide 17 17 Slide 18 18 Slide 19 19 Slide 20 20 Slide 21 21